Real-world data suggest that Erleada may offer an advantage over other treatment options for patients with metastatic ...

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety ...

Pfizer Inc. (NYSE:PFE) is one of the 13 Best Large Cap Stocks to Buy Right Now. On July 10, Pfizer Inc. (NYSE:PFE) shared ...

Pfizer and Astellas’ Xtandi (enzalutamide) has improved overall survival (OS) in patients with non-metastatic ...

Results from the Phase III EMBARK trial show that in combination with leuprolide, Xtandi (enzalutamide) demonstrated a ...

The market of prostate cancer is currently at 27B and is expected to reach 50B by 2017 (with 17B in the diagnosis and screening segment, and 14.3B for surgery and radiation, and approx. 15-20B ...

Xtandi is the market leader among new hormonal therapies for prostate cancer, with Astellas recording $2.7 billion in sales between March and end-December 2019 – the first nine months of its ...

The company received FDA approval to market Xtandi as a prostate cancer medication in 2012 and reported $1.9 billion in worldwide sales of the drug in 2015.

In the latest gambit to lower the cost of a pricey cancer medicine, three advocacy groups are pushing the Biden administration to use federal laws to license Xtandi patents.

Pfizer and Astellas have new survival data for their prostate cancer drug Xtandi that could help it fend off growing competition in the market. The results of the phase 3 PROSPER trial show that ...